ECTRIMS Action Center
Welcome to the ECTRIMS Action Center, your go-to source for the latest updates and expert insights from the 2024 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Here you’ll find leading neurologists share evidence-based information so you can stay ahead of emerging multiple sclerosis advancements.
Genetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
NeuroFrontiersGenetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
NeuroFrontiersUnderstanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
Navigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
NeuroFrontiersNavigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
NeuroFrontiersDecoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
Timing Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
NeuroFrontiersTiming Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
Clemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
NeuroFrontiersClemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
- advertisement
- 09/24/2025
- 09/23/2025
- 09/22/2025